Navigation Links
Shire Delivers Strong 2012 Results and Reiterates Confidence in 2013
Date:2/14/2013

sales were up 46%(1) compared to sales reported by Shire subsequent to acquisition in 2011. On a full year basis, sales for DERMAGRAFT were down 21% reflecting the impact of an ongoing restructuring of the RM sales and marketing organization and the implementation of a new commercial model, all of which is expected to position DERMAGRAFT for future sales growth.

  1. Shire acquired DERMAGRAFT through its acquisition of ABH on June 28, 2011 and reported revenues from DERMAGRAFT of $105.3m relating to the post acquisition period in 2011.

FIRAZYR - Hereditary Angioedema

Reported FIRAZYR sales growth (252%) was driven largely by the first full year of sales in the US market, following launch of FIRAZYR in the market in Q4 2011.

ADDERALL XR - ADHD

ADDERALL XR product sales decreased (-19%) in 2012 as a result of lower US prescription demand following the introduction of a new generic competitor and the impact of the accounting for the legal settlement with Impax, which reduced reported product sales by $42 million in 2012, in addition to the effect of product destocking in 2012 compared to stocking in 2011 and, higher sales deductions. These negative factors were partially offset by the benefit of a price increase taken during 2012.

2.    Royalties

Product Royalties to Shire $M Year on year growth CER 3TC and ZEFFIX 91.6 +11% +11% ADDERALL XR 70.3 -34% -34% FOSRENOL 53.3 +15% +15% Other 26.4 -44% -42% Total 241.6 -15% -15%

Royalties from 3TC and ZEFFIX include one-time royalty income of $38 million in respect of prior periods due to resolution of the disagreement between Shire, GSK and ViiV as to how the royalty rate for these products should be applied. This one-time income more than offset the underlying decline in 3TC and Zeffix royalties as a result of increased competition and the expiry of patents in certain territories in 2012.

Royalties from
'/>"/>

SOURCE Shire plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine technology :

1. Shire Regenerative Medicine and HealTogether Partner with Celebrity Chef Charles Mattocks to Raise Awareness of Diabetes and its Complications
2. NYSE Hot Stocks Earnings Forecast: Wells Fargo, Eli Lilly, Berkshire Hathaway, Coca-Cola, Valero Energy, and Altria Group
3. Shire Leads New Initiative to Reveal Challenges Facing Rare Disease Community
4. Dr Steven Gillis to Join Shire Board of Directors
5. Shire Second Quarter Product Sales Up 16%
6. Shire Announces that the US Food and Drug Administration has Responded to its Citizen Petition for Adderall XR and has Approved One Abbreviated New Drug Application for Generic Adderall XR
7. Shire to Present Scientific Data Across Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting May 5-9
8. Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth
9. Maroon 5 Lead Singer Adam Levine and Shire Announce "The Own It Project," Encouraging Adults with Attention-Deficit/Hyperactivity Disorder to Tell Their Stories Through a National Contest
10. Study Delivers Investment Benchmarks across Key New Product Launch Activities in Pharmaceutical Sector
11. SIS Delivers Advanced Interoperability With Siemens Soarian Clinicals To Improve Efficiency, Communication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Intarcia Therapeutics, Inc. today announced the presentation ... ITCA 650 (continuous subcutaneous delivery of exenatide) in type ... the 50 th Annual Meeting of the European ... the open-label, phase 3 FREEDOM-HBL (high baseline) trial showed ... poorly controlled type 2 diabetes. The results were presented ...
(Date:9/18/2014)... , September 19, 2014 ... Markets ( http://www.researchandmarkets.com/research/qqjrnh/global_molecular ) has announced the ... Market 2014-2018" report to their offering. ... Cytogenetics involves the study of chromosomes using ... functions of genes and chromosomes. It plays ...
(Date:9/18/2014)... -- PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results for ... 30, 2014. Quarter Ended June 30, ... 2014 increased $492,000, or 18%, to $3.2 million from ... 2013, due primarily to an increase of $746,000 in ... largest customer, partially offset by an aggregate decrease in ...
Breaking Medicine Technology:Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 2Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 3Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 2Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 3Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 4Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 5Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 6Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 7Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 8Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 9Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 10Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 11Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 12Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 13
... Carnegie Mellon University,s Bone Tissue Engineering Center ... limbs in combat. (Logo: http://photos.prnewswire.com/prnh/20020422/CMULOGO) ... Hollinger, director of the center, and Professor Krzysztof ... Department of Defense research grant to develop a ...
... Stanley M. Chesley of the Cincinnati, Ohio-based law firm of ... a major class action lawsuit against DePuy Orthopaedics, Inc. and ... Johnson and Johnson recently recalled over 90,000 ASR XL Acetabular ... causing patients to undergo hip replacement surgery. ...
Cached Medicine Technology:CMU's Bone Tissue Engineering Center Receives Defense Department Research Grant to Help Injured Soldiers 2
(Date:9/19/2014)... led by Medical College of Wisconsin (MCW) scientists has identified ... in rats, mice and in humans. The findings are published ... , Leah Solberg Woods, Ph.D., associate professor of pediatrics ... Wisconsin Research Institute, led the study and is the corresponding ... identified a gene called Tpcn2 in which a variant was ...
(Date:9/19/2014)... Top10BestSEOHosting.com today compares many professional Windows web ... Bluehost are the best suppliers of 2014. Clients ... (including VPS and cloud hosting) at affordable rates ... , HostMonster ( http://www.hostmonster.com/track/seohosts ) helps business companies ... of the cost. As a top rated hosting ...
(Date:9/19/2014)... cancer do not receive any palliative care, reveals new ... ESMO 2014 Congress in Madrid, Spain, 26-30 September. The ... time as 15 new oncology centres in Europe, Canada, ... title of ,ESMO Designated Centre of Integrated Oncology and ... oncology consultant at the Institute of Oncology Bucharest, Romania, ...
(Date:9/19/2014)... San Jose, California (PRWEB) September 19, 2014 ... – Immunoassays are ligand assays used for detection ... antibodies in a given sample. Driven by steady ... overall healthcare industry, the global immunoassay systems market ... incidence of debilitating conditions, such as diabetes, cardio-vascular ...
(Date:9/19/2014)... TN (PRWEB) September 19, 2014 ... has been named a finalist for the 2014 ... founder and president Tammy Hawes has been selected ... the Year. The Nashville Area Chamber of Commerce ... these awards to recognize the accomplishments of companies ...
Breaking Medicine News(10 mins):Health News:Top10BestSEOHosting.com: They Are Best Windows Web Hosting Suppliers Of 2014 2Health News:Patients with advanced, incurable cancer denied palliative care 2Health News:Patients with advanced, incurable cancer denied palliative care 3Health News:Patients with advanced, incurable cancer denied palliative care 4Health News:Growing Preference for Non-Invasive Diagnostics Spurs Growth in the Global Immunoassay Systems Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Growing Preference for Non-Invasive Diagnostics Spurs Growth in the Global Immunoassay Systems Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Growing Preference for Non-Invasive Diagnostics Spurs Growth in the Global Immunoassay Systems Market, According to New Report by Global Industry Analysts, Inc. 4Health News:Virsys12 and Founder Tammy Hawes Each Named 2014 NEXT Awards Finalists 2Health News:Virsys12 and Founder Tammy Hawes Each Named 2014 NEXT Awards Finalists 3
... for about 10% to 20 % of women menopausal period ... sweats, hot// flashes (sensation of heat which comes on all ... Therapy (HRT) is the conventional treatment of choice that is ... period. Hormone therapy offers great relief from hot flashes and ...
... Telemedicine, the amalgamation of medicine and modern communications technology, ... monitor patients at a distance means they// can leave ... doctor, which also saves money. ,Christian Weigand, ... Circuits in Erlangen, Germany, said telemedicine could help people ...
... olive oil, glycerine and egg yolk would prevent ... ,The journal of Catheterization and Cardiovascular Interventions ... by Michael Savage, M.D., director, Cardiac Catheterization Laboratory ... mixture is not swallowed, Dr. Savage explains. Rather, ...
... the aging brain produces progressively fewer new nerve ... scientists said the finding, made in rodents, refutes ... cells persist in the aging brain. ... various neurodegenerative disorders, including Alzheimer's disease, dementia and ...
... diabetes and heart disease, lifestyle changes are making a ... study suggests that by reducing the intake beverages saturated ... their risk of developing cardiac diseases in the future. ... hypertension and type-2 diabetes has largely dealt with adults," ...
... signal an oncoming cold, many people reach for what ... tea or capsule containing //echinacea. In the first study ... bacteria in the gastrointestinal tract, research at the University ... side effects with this common herbal remedy. ,Although ...
Cached Medicine News:Health News:Natural Remedies Ineffective to Ease Menopausal Symptoms:study 2Health News:Telemedicine Offers New Possibilities in Health Care 2Health News:Olive Oil Emulsions Prevent Cardiac Bypass Surgery 2Health News:Stem Cell Activity Deciphered in the Aging Brain 2Health News:Cardiac Risk is Reduced by Cutting the Sugar in Your Drink 2Health News:Cardiac Risk is Reduced by Cutting the Sugar in Your Drink 3Health News:Echinacea: Cold-Season Cure or Risk? 2
Reusable, stainless steel trephine with handle....
Reusable, stainless steel trephine with handle....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Medicine Products: